Trending Stocks : Ariad Pharmaceuticals (NASDAQ:ARIA), Checkpoint (NYSE:CKP), Computer Sciences (NYSE:CSC), Seattle Genetics Inc. (NASDAQ:SGEN), Infoblox Inc. (NYSE:BLOX)

US specialty pharma firm Ariad Pharmaceuticals (NASDAQ:ARIA) has granted Israel’s Medison Pharma exclusive rights to commercialize Iclusig (ponatinib) in Israel for patients with Philadelphia-positive (Ph+) leukemias. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Healthcare sector. Its weekly performance is -12.09%. On last trading day company shares ended up $5.38. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) distance from 50-day…

Read More

Eye Catching Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Informatica (NASDAQ:INFA), Canadian Pacific Railway Limited (NYSE:CP), EnLink Midstream, LLC (NYSE:ENLC), Trex (NYSE:TREX)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. Currently there are 5 analysts that rate ARIAD Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s stock on 31 July traded at beginning with…

Read More

Healthcare ACtive Stocks: MannKind (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Bristol-Myers Squibb Co (NYSE:BMY)

MannKind Corporation (NASDAQ: MNKD) is a small company based in Valencia, California, poised to launch its FDA approved drug, Afrezza, as treatment indications for both Type 1 and Type 2 diabetes. Despite near unanimous backing from experts at the Advisory Committee (ADCOM) and the medical community, Mr. Market is still pessimistic on the company.  MannKind Corporation (NASDAQ:MNKD)…

Read More

Trending Stocks – Priceline (NASDAQ:PCLN) , Ariad Pharmaceuticals (NASDAQ:ARIA) , Hi-Crush Partners (NYSE:HCLP) , Rackspace (NYSE:RAX) , SMFG)

Priceline Group Inc (NASDAQ:PCLN) Director Jeffery H. Boyd sold 3,000 shares of Priceline Group stock on the open market in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $1,228.00, for a total transaction of $3,684,000.00. Following the sale, the director now directly owns 194,125 shares of the company’s…

Read More